This was partly offset by improved retail contributions in the U.S.

Retail Pharmacy and growth investments in U.S. Adjusted operating income was $1.0 billion, a decrease of 42.2 percent on a constant currency basis, reflecting lower volumes of COVID-19 vaccinations and testing compared to the peak prior year period, planned payroll and IT investments in U.S. Operating loss in the quarter reflects a $6.5 billion pre-tax charge for opioid-related claims and litigation. Operating loss was $6.2 billion in the first quarter compared to operating income of $1.3 billion in the year-ago quarter. Healthcare M&A of 280 basis points, sales growth was 3.2 percent on a constant currency basis. Excluding the negative impact from AllianceRx Walgreens of 485 basis points and the positive contributions from U.S. WBA first quarter sales decreased 1.5 percent from the year-ago quarter to $33.4 billion, an increase of 1.1 percent on a constant currency basis. Execution across segments reinforces our confidence in achieving full-year guidance, and our strategic actions are creating long-term shareholder value.' Our core retail pharmacy businesses in both the United States and United Kingdom remain resilient in challenging operating environments.

Healthcare segment to scale and profit, including the recent VillageMD acquisition of Summit Health. We're making significant progress in driving our U.S. 'WBA delivered a solid start to the fiscal year, as we continue to accelerate our transformation to a consumer-centric healthcare company. (Nasdaq: WBA) today announced financial results for the first quarter of fiscal 2023, which ended November 30, 2022.Ĭhief Executive Officer Rosalind Brewer said: Increased clarity into the Company's long-term growth algorithm, building to low-teens adjusted EPS growth in fiscal year 2025 and beyondĭEERFIELD, Ill.-( BUSINESS WIRE)-Walgreens Boots Alliance, Inc. Healthcare targets raised with Summit Health announcement on November 7, 2022, including fiscal year 2025 sales goal to $14.5 billion to $16.0 billion, up from $11.0 billion to $12.0 billion previously, and positive adjusted EBITDA expected for the segment by the end of fiscal year 2023 Raising full-year sales guidance to $133.5 billion to $137.5 billion reflecting Summit Health acquisition, refreshed currency rates, and first quarter sales ahead of expectations Maintaining full-year adjusted EPS guidance of $4.45 to $4.65 as strong core business growth is more than offset by lapping fiscal year 2022 COVID-19 execution, and currency headwinds Sold 19.2 million shares of AmerisourceBergen common stock in November and December, with after-tax cash proceeds of $3 billionįiscal 2023 outlook and long-term growth outlook Healthcare segment sales and path to profitability Invested $3.5 billion in debt and equity to support VillageMD's acquisition of Summit Health, which closed January 3, 2023, accelerating U.S. Healthcare M&A of 280 basis points, sales growth was 3.2 percent on a constant currency basis Results On Track to Achieve Full-Year Adjusted EPS Guidance įirst quarter loss per share* was $4.31 compared to earnings per share (EPS*) of $4.13 in the year-ago quarter reflecting a $6.5 billion pre-tax charge recognized in connection with the previously announced opioid litigation settlement frameworks and certain other opioid-related mattersĪdjusted EPS decreased 30.8 percent to $1.16, down 29.9 percent on a constant currency basis against strong growth of 53.1 percent in the year-ago quarter reflecting higher COVID-19 vaccine volumesįirst quarter sales decreased 1.5 percent year-over-year, to $33.4 billion, up 1.1 percent on a constant currency basis excluding the negative impact from AllianceRx Walgreens of 485 basis points and the positive contributions from U.S.

Walgreens timing